Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 542-552

  Okusaka, Takuji ^a   Ueno, Hideki ^a   Ikeda, Masafumi ^b   Morizane, Chigusa ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Acyclic retinoid; Hepatocellular carcinoma; NIK 333; Peretinoin; Phase I

Indexed keywords

ANTIHYPERTENSIVE AGENT; PERETINOIN; PLACEBO; RETINOID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FOOD DRUG INTERACTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; HEADACHE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; NAIL DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 79957576345     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00800.x     Document Type: Article

References (13)

1. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979; 38: 2528-34.
2. Muto Y, Moriwaki H, Omori M. In vitro binding affinity of novel synthetic polyprenoids (polyprenoic acids) to cellular retinoid-binding proteins. Gann 1981; 72: 974-7.
3. Muto Y, Moriwaki H, Ninomiya M etal. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561-7.
4. Moriwaki H, Yasuda I, Shiratori Y etal. Deletion of serum lectin-reactive α-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997; 3: 727-31.
5. Yamada Y, Shidoji Y, Fukutomi Y etal. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994; 10: 151-8.
6. Fukutomi Y, Omori M, Muto Y etal. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of α-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res 1990; 81: 1281-5.
7. Nakamura N, Shidoji Y, Yamada Y etal. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995; 207: 382-8.
8. Nakamura N, Shidoji Y, Moriwaki H etal. Apoptosis in human hepatoma cell line induced by 4, 5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of Transforming Growth Factor-α. Biochem Biophys Res Commun 1996; 219: 100-4.
9. Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor α is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009; 100: 369-74.
10. Shimizu M, Sakai H, Moriwaki H. Chemoprevention of hepatocellular carcinoma by acyclic retinoid. Front Biosci 2011; 16: 759-69.
11. Piraccini BM, Iorizzo M, Antonucci A etal. Drug-induced nail abnormalities. Expert Opin Drug Saf 2004; 3: 57-65.
12. Onder M, Oztaş MO, Oztaş P. Isotretinoin-induced nail fragility and onycholysis. J Dermatolog Treat 2001; 12: 115-16.
13. Marsden JR. Lipid metabolism and retinoid therapy. Pharmacol Ther 1989; 40: 55-65.